<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188928</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 80185-G23</org_study_id>
    <nct_id>NCT01188928</nct_id>
  </id_info>
  <brief_title>LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)</brief_title>
  <official_title>A Phase 3 Study Comparing Once Daily Treatment With Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension With Betamethasone 0.5 mg/g (as Dipropionate) in the Topical Suspension Vehicle, Calcipotriol 50 mcg/g in the Topical Suspension Vehicle and the Topical Suspension Vehicle Alone in Subjects With Psoriasis Vulgaris on Non-scalp Regions of the Body (Trunk and/or Limbs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus
      Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when
      used individually as monotherapy in the topical suspension vehicle (betamethasone
      dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension
      vehicle) and with the topical suspension vehicle alone in the treatment of psoriasis vulgaris
      on the non-scalp regions of the body (trunk and/or limbs) in a large phase 3 study. This
      comparison will ensure a more informed assessment of the benefit/risk ratio of Calcipotriol
      50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension while also
      establishing the optimal treatment duration in psoriasis vulgaris on the non-scalp regions of
      the body (trunk and/or limbs).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8</measure>
    <time_frame>week 8</time_frame>
    <description>The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with 'Controlled disease' according to the IGA. 'Controlled disease' is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change in PASI From Baseline to Week 4</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change in PASI From Baseline to Week 8</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject's psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1152</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 80185</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcipotriol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcipotriol 50 mcg/g in the topical suspension vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical suspension vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The topical suspension vehicle alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol plus betamethasone</intervention_name>
    <description>Topical suspension once daily for up to 8 weeks.</description>
    <arm_group_label>LEO 80185</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone-17,21-dipropionate</intervention_name>
    <description>Topical suspension once daily for up to 8 weeks.</description>
    <arm_group_label>Betamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriene</intervention_name>
    <description>Topical suspension once daily for up to 8 weeks.</description>
    <arm_group_label>Calcipotriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical suspension vehicle</intervention_name>
    <description>Topical suspension once daily for up to 8 weeks.</description>
    <arm_group_label>Topical suspension vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent obtained prior to any trial related activities
             (including any washout period).

          -  Aged 18 years or above

          -  Either sex

          -  Any race or ethnicity

          -  Attending a hospital outpatient clinic or the private practice of a board certified
             dermatologist.

          -  Clinical diagnosis of stable plaque psoriasis vulgaris of at least 6 months duration
             involving the non-scalp regions of the body (trunk and/or limbs) amenable to treatment
             with a maximum of 100 g of topical medication per week.

          -  An investigator's global assessment of disease severity (IGA) of mild or moderate on
             the body (trunk and/or limbs) at Day 0 (Visit 1).

          -  A minimum modified Psoriasis Area and Severity Index (PASI) score for extent of 2 in
             at least one body region (i.e. psoriasis affecting at least 10% of arms, and/or 10% of
             trunk, and/or 10% of legs)

          -  Females of childbearing potential must have a negative pregnancy test at Day 0 (Visit
             1).

          -  Females of childbearing potential must agree to use a highly effective method of birth
             control during the study. A highly effective method of birth control is defined as one
             which results in a low failure rate (less than 1% per year) such as implants,
             injectables, combined oral contraceptives, some intrauterine devices, sexual
             abstinence or vasectomised partner. The patients must have used the contraceptive
             method continually for at least 1 month prior to the pregnancy test, and must continue
             using the contraceptive method for at least 1 week after the last application of study
             medication. A female is defined as not of child-bearing potential if she is
             postmenopausal (12 months with no menses without an alternative medical cause), or
             surgically sterile (tubal ligation/section, hysterectomy or bilateral ovariectomy).

          -  Able to communicate with the investigator and understand and comply with the
             requirements of the study.

        Exclusion Criteria:

          -  Systemic treatment with biological therapies, whether marketed or not, with a possible
             effect on psoriasis vulgaris within the following time periods prior to randomisation:

               -  etanercept - within 4 weeks prior to randomisation

               -  adalimumab, alefacept, infliximab - within 2 months prior to randomisation

               -  ustekinumab - within 4 months prior to randomisation

               -  experimental products - within 4 weeks/5 half-lives (whichever is longer) prior
                  to randomisation

          -  Systemic treatment with all other therapies with a possible effect on psoriasis
             vulgaris (e.g., corticosteroids, retinoids, methotrexate, cyclosporine and other
             immunosuppressants) within 4 weeks prior to randomisation.

          -  PUVA or Grenz ray therapy within 4 weeks prior to randomisation.

          -  UVB therapy within 2 weeks prior to randomisation.

          -  Any topical treatment of the trunk and/or limbs (except for emollients) within 2 weeks
             prior to randomisation.

          -  Topical treatment for other relevant skin disorders on the face and flexures (e.g.,
             facial and flexural psoriasis, eczema) with class 1- 5 corticosteroids or vitamin D
             analogues within 2 weeks prior to randomisation.

          -  Topical treatment for other relevant skin disorders on the scalp (e.g. scalp
             psoriasis) with class 1-5 corticosteroids, vitamin D analogues or prescription
             shampoos within 2 weeks prior to randomisation.

          -  Planned initiation of, or changes to, concomitant medication that could affect
             psoriasis vulgaris (e.g. beta blockers, anti-malarials, lithium, ACE inhibitors)
             during the study.

          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.

          -  Subjects with any of the following conditions present on the treatment area: viral
             (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections,
             parasitic infections, skin manifestations in relation to syphilis or tuberculosis,
             rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae,
             fragility of skin veins, icthyosis, acne rosacea, ulcers and wounds.

          -  Known or suspected disorders of calcium metabolism associated with hypercalcaemia.

          -  Known or suspected severe renal insufficiency or severe hepatic disorders.

          -  Known or suspected hypersensitivity to component(s) of the investigational products.

          -  Current participation in any other interventional clinical study.

          -  Subjects who have received treatment with any non-marketed drug substance (i.e. an
             agent which has not yet been made available for clinical use following registration)
             within the 4-week period prior to randomisation or longer, if the class of substance
             required a longer washout as defined above (e.g. biological treatments).

          -  Planned excessive exposure to the sun during the study that may affect the psoriasis
             vulgaris.

          -  Previously randomised in this study.

          -  Females who are pregnant, have a positive pregnancy test at Day 0 (Visit 1), or are
             breast-feeding. Females of child-bearing potential wishing to become pregnant during
             the study, or not using an adequate method of contraception during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Menter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Dermatology, Baylor Research Institute, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Tyring, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Clinical Studies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven A Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Clinical Research Center of San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David J Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatologic Surgery Specialists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Progressive Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tiffani K Hamilton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Dermatology, Vein &amp; Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel M Stewart, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan Center for Research Corp.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John J Goodman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palm Beach Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terry Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J&amp;S Studies, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dow Stough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Burke Pharmaceutical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerry Bagel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psoriasis Treatment Center of Central NJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James A Solomon, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ameriderm Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George J Murakawa, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Somerset Skin Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Bukhalo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altman Dermatology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deaconess Clinic, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaime D Weisman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peachtree Dermatology Associates Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Kantor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Florida Dermatology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Rodriguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Associates and Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Swinyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Research Center, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alicia Bucko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Dermatology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johnathan Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gwinnett Clinical Research Center, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William P Werschler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premier Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Lebwohl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Swinehart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado Medical Research Center, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Kempers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Clinical Study Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dale Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Surgery Medical Group, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Guenthner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Clinical Trials Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Dawes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dawes Fretzin Clinical Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Glazer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glazer Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl G Heine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karl G. Heine, M. D. Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fasahat Hamzavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamzavi Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Samady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Artis P Truett III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Owensboro Dermatology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phoebe Rich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Dermatology and Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Shecter, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>VISIONS CLINICAL RESEARCH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Haber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haber Dermatology and Cosmetic Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Kerr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Horizons Clinical Research Center, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Fivenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>David Fivenson, MD Dermatology, PLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Nahm, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Nahm, MD, Ph.D., Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Grekin, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grekin Skin Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph F Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose E Mendez, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Dermatology Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M Stoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Research Centers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul S Yamauchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Nossa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Dermatology Group, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chernila Selbert Alan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DBA Torrance Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brent M Boyce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Great Lakes Research Group, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David B Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew King, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King-Maceyko Dermatology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Hren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Triangle Medical Research Associates, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elyse S Rafal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Derm Research Center of New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Siebenlist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Dermatolgy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Stein Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura K Ferris, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Hughes Tichy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials of Texas, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane M Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anderson &amp; Collins Clinical Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles P Hudson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hudson Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amy M Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Horizon Research Group, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Green, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawrence J. Green, MD, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Horizon Research Group, Inc</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DBA Torrance Clinical Research</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists, Inc.</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Surgery Medical Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Nahm, MD, Ph.D., Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Medical Research Group, Inc.</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Centers</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center, LLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates and Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida Dermatology Associates, PA</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ameriderm Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology, Vein &amp; Research Center</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peachtree Dermatology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Surgery Specialists, PC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Clinical Research Center, Inc</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Hts</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glazer Dermatology</name>
      <address>
        <city>Buffalo Grove</city>
        <state>Illinois</state>
        <zip>60089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic, Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Dermatology</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Owensboro Dermatology Associates</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence J. Green, MD, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Fivenson, MD Dermatology, PLC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group, Inc</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Research Corp.,</name>
      <address>
        <city>Clinton Twp</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Skin Centre</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karl G. Heine, M. D. Dermatology</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central NJ</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson &amp; Collins Clinical Research, Inc.</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Dermatology Group, PC</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research Center of New York</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triangle Medical Research Associates, LLC</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology and Cosmetic Surgery</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King-Maceyko Dermatology Associates</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Dermatology, Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <results_first_submitted>January 21, 2013</results_first_submitted>
  <results_first_submitted_qc>February 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2013</results_first_posted>
  <disposition_first_submitted>January 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 11, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 14, 2013</disposition_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject’s first visit was on 27-SEP-2010 and the last subject’s last visit was on 29-MAR-2011. Hence the study had a duration of 26 weeks.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LEO 80185</title>
          <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension</description>
        </group>
        <group group_id="P2">
          <title>Betamethasone</title>
          <description>Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle</description>
        </group>
        <group group_id="P3">
          <title>Calcipotriol</title>
          <description>Calcipotriol 50 mcg/g in the topical suspension vehicle</description>
        </group>
        <group group_id="P4">
          <title>Topical Suspension Vehicle</title>
          <description>The topical suspension vehicle alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="482"/>
                <participants group_id="P2" count="479"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="444"/>
                <participants group_id="P2" count="417"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LEO 80185</title>
          <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension</description>
        </group>
        <group group_id="B2">
          <title>Betamethasone</title>
          <description>Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle</description>
        </group>
        <group group_id="B3">
          <title>Calcipotriol</title>
          <description>Calcipotriol 50 mcg/g in the topical suspension vehicle</description>
        </group>
        <group group_id="B4">
          <title>Topical Suspension Vehicle</title>
          <description>The topical suspension vehicle alone</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="482"/>
            <count group_id="B2" value="479"/>
            <count group_id="B3" value="96"/>
            <count group_id="B4" value="95"/>
            <count group_id="B5" value="1152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" spread="13.4"/>
                    <measurement group_id="B2" value="48.5" spread="13.8"/>
                    <measurement group_id="B3" value="48" spread="13.7"/>
                    <measurement group_id="B4" value="49.4" spread="13.0"/>
                    <measurement group_id="B5" value="48.6" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="462"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="284"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="482"/>
                    <measurement group_id="B2" value="479"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="1152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Controlled Disease According to the Investigator’s Global Assessment of Disease Severity (IGA) at Weeks 4</title>
        <description>The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with ‘Controlled disease’ according to the IGA. ‘Controlled disease’ is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80185</title>
            <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle</description>
          </group>
          <group group_id="O3">
            <title>Calcipotriol</title>
            <description>Calcipotriol 50 mcg/g in the topical suspension vehicle</description>
          </group>
          <group group_id="O4">
            <title>Topical Suspension Vehicle</title>
            <description>The topical suspension vehicle alone</description>
          </group>
        </group_list>
        <measure>
          <title>Controlled Disease According to the Investigator’s Global Assessment of Disease Severity (IGA) at Weeks 4</title>
          <description>The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with ‘Controlled disease’ according to the IGA. ‘Controlled disease’ is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="479"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Controlled Disease According to the Investigator’s Global Assessment of Disease Severity (IGA) at Weeks 8</title>
        <description>The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with ‘Controlled disease’ according to the IGA. ‘Controlled disease’ is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.</description>
        <time_frame>week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80185</title>
            <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle</description>
          </group>
          <group group_id="O3">
            <title>Calcipotriol</title>
            <description>Calcipotriol 50 mcg/g in the topical suspension vehicle</description>
          </group>
          <group group_id="O4">
            <title>Topical Suspension Vehicle</title>
            <description>The topical suspension vehicle alone</description>
          </group>
        </group_list>
        <measure>
          <title>Controlled Disease According to the Investigator’s Global Assessment of Disease Severity (IGA) at Weeks 8</title>
          <description>The IGA was chosen as the primary efficacy assessment. The primary endpoint is subjects with ‘Controlled disease’ according to the IGA. ‘Controlled disease’ is defined as clear or almost clear for subjects with moderate disease at baseline and clear for subjects with mild disease at baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="479"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Change in PASI From Baseline to Week 4</title>
        <description>At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject’s psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80185</title>
            <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle</description>
          </group>
          <group group_id="O3">
            <title>Calcipotriol</title>
            <description>Calcipotriol 50 mcg/g in the topical suspension vehicle</description>
          </group>
          <group group_id="O4">
            <title>Topical Suspension Vehicle</title>
            <description>The topical suspension vehicle alone</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change in PASI From Baseline to Week 4</title>
          <description>At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject’s psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.</description>
          <units>percentage of change in PASI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="479"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.4" spread="30.2"/>
                    <measurement group_id="O2" value="-42.7" spread="29.4"/>
                    <measurement group_id="O3" value="-32.2" spread="27.3"/>
                    <measurement group_id="O4" value="-17.4" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Change in PASI From Baseline to Week 8</title>
        <description>At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject’s psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80185</title>
            <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension</description>
          </group>
          <group group_id="O2">
            <title>Betamethasone</title>
            <description>Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle</description>
          </group>
          <group group_id="O3">
            <title>Calcipotriol</title>
            <description>Calcipotriol 50 mcg/g in the topical suspension vehicle</description>
          </group>
          <group group_id="O4">
            <title>Topical Suspension Vehicle</title>
            <description>The topical suspension vehicle alone</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change in PASI From Baseline to Week 8</title>
          <description>At all treatment phase visits the (sub)investigator made an assessment of the extent and severity of clinical signs of the subject’s psoriasis using a modified PASI score (Psoriasis Area and Severity Index) To make up the score, the three features of a psoriatic plaque redness, scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. The extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.</description>
          <units>percentage of change in PASI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="479"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.8" spread="34.4"/>
                    <measurement group_id="O2" value="-48.6" spread="35.8"/>
                    <measurement group_id="O3" value="-43.6" spread="34.1"/>
                    <measurement group_id="O4" value="-20.9" spread="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LEO 80185</title>
          <description>Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension</description>
        </group>
        <group group_id="E2">
          <title>Betamethasone</title>
          <description>Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle</description>
        </group>
        <group group_id="E3">
          <title>Calcipotriol</title>
          <description>Calcipotriol 50 mcg/g in the topical suspension vehicle</description>
        </group>
        <group group_id="E4">
          <title>Topical Suspension Vehicle</title>
          <description>The topical suspension vehicle alone</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.00</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.00</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting or presenting a manuscript relating to the clinical trial to a publisher, reviewer, or other outside person, the Investigator shall provide to LEO a copy of all such manuscripts, and LEO shall have rights to review and comment. Upon the request of LEO the Investigator shall remove any confidential information (other than results generated by the Investigator) prior to submitting or presenting the manuscripts.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>Leo Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

